Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that data from the cell adhesion experiment shown in Fig. 11 were strikingly similar to data appearing in different form in Fig. 6B in another article written by different authors at different research institutes [Huang Z, Li J, Du S, Tang Y, Huang L, Xiao L and Tong P: FKBP14 overexpression contributes to osteosarcoma carcinogenesis and indicates poor survival outcome. Oncotarget 7: 39872‑39884, 2016].  Owing to the fact that the contentious data in the above article had already been published prior to its submission to Molecular Medicine Reports, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [Molecular Medicine Reports 17: 2153‑2160, 2018; DOI: 10.3892/mmr.2017.8173].

Lung cancer is the leading cause of global cancer-associated mortality. Genomic alterations in lung cancers have not been widely characterized, however, the molecular mechanism of tumor initiation and progression remain unknown, and no molecularly targeted have been specifically developed for its treatment and diagnosis. The present study observed the upregulation of Aldo-keto reductase family 1 member Bio10 (AKR1B10) lung cancer tissues by analyzing two public lung cancer gene expression datasets. Further experiments in silencing AKR1B10 demonstrated that the expression of AKR1B10 was associated with cell proliferation, cell cycle, adhesion and invasion, as well as extracellular-signal-regulated kinase/mitogen activated protein kinase signal pathway. The overexpression of AKR1B10 in lung cancer indicates the important role of AKR1B10 in tumorigenesis. These findings suggest that AKR1B10 could be a potential diagnosis and treatment mark of lung cancer.

BACKGROUND:The seventh edition of the tumor, node, metastasis Classification of Malignant Tumors is due to be published in 2009. The recommendations of International Association for the Study of Lung Cancer for changes to the T descriptors have been published. We combined this new parameter with other well-established prognostic factors and performed multivariate survival analyses to validate its value in Chinese stage I non-small cell lung cancer (NSCLC). METHODS:We try to validate the new staging project in 325 patients who underwent complete surgical resection for stage I NSCLC in Single Institution of Shanghai Chest Hospital from 1998 to 2003. Variables in the analysis included age, gender, performance status, history of smoking, pathologic type, type of resection (pneumonectomy, lobectomy, and bilobectomy), tumor size (greatest dimension of tumor), T-status (T1 or T2), type of lymph node resection (systematic mediastinal lymphadenectomy or mediastinal lymph node sampling), lymphovascular vessel invasion, and adjuvant chemotherapy. RESULTS:The 5-year overall survival (OS) of patients whose tumor measured no larger than 2 cm in largest diameter or larger than 2 cm but no larger than 3 cm were 75.49 and 74.58%, respectively. For those with tumors measured larger than 3 cm but smaller than 5 cm or larger than 5 cm but smaller than 7 cm were 60.87 and 55.63%. The 5-year OS of patients whose tumor measured larger than 7 cm was 46.15% (p = 0.025). The 5-year disease-free survival rates of patients whose tumor measured no larger than 2 cm in largest diameter or larger than 2 cm but no larger than 3 cm were 67.65 and 66.67%, respectively. For those with tumors measured larger than 3 cm but smaller than 5 cm or larger than 5 cm but smaller than 7 cm were 53.14 and 52.63%. The 5-year disease-free survival rate of patients whose tumor measured larger than 7 cm was 30.77% (p = 0.009). Multivariate analyses revealed that age, gender, type of resection (pneumonectomy, lobectomy, and bilobectomy), tumor size (greatest dimension of tumor), type of lymph node resection (systematic mediastinal lymphadenectomy or mediastinal lymph node sampling), and lymphovascular vessel invasion were significant predictive factors for OS. CONCLUSIONS:The tumor size is a significant independent prognostic factors in stage I NSCLC.

22210 Background: The IASLC Lung Cancer Staging Project recommend changes in the T classification are to subclassify T1 into T1a and T1b, and T2 into T2a and T2b; and to reclassify T2c and additional nodule(s) in the same lobe as T3. But other well-known clinical and histopathological factors were also possible prognostic factors. Methods: We try to validate the new staging project in 325 patients who underwent complete surgical resection for stage I NSCLC in Single Institution of Shanghai Chest Hospital from 1998 to 2003. All the patients were followed up four years. Data were analyzed by SPSS 11.0 software. Results: The pT1NOR0 was divided into pT1a ≤2 cm (n=28) and pT1b>2 to 3 cm (n=15) and pT2NOR0 was divided into pT1a ≤2 cm (n=40), pT1b>2 to 3 cm (n=84),pT2a>3 to 5 cm (n=107), pT2b>5 to 7 cm (n=38), and pT2c >7 cm (n=13). The results validate the IASLC recommend changes(table 1). Table 1, Comparisons of Overall Survival between Tumor Size The 4-year survival rate for patients with systematic mediastinal lymphadenectomy (n=68) was 72.75% while patients with mediastinal lymph node sampling (n=257) was 49.63% (p=0.026). Female patients (n=116) was associated with a better survival than men's (n=209; 77.76% vs 68.13%, p=0.022). Patients without lymphovascular invasion (n=309) was associated with a better survival than patients with lymphovascular invasion (n=16; 72.75% vs 49.63%, p=0.025). Conclusions: We get the same results which shows the tumor diameter is significant independent prognostic factors in non-small cell lung cancer and lymphovascular invasion may add new information of the current TNM classification. Mediastinal lymphadenectomy is also a significant independent prognostic factor in resection non-small cell lung cancer. It needs further research. Stage T 4-year survival rate P value T1NOR0 pT1a ≤2 cm (n = 28) 78.42% 0.6488 pT1b >2 to 3 cm (n = 15) 74.33% T2NOR0 pT1a ≤2 cm (n = 40) 79.15% 0.027 pT1b >2 to 3 cm (n = 84) 79.28% pT2a >3 to 5 cm (n = 107) 66.41% pT2b >5 to 7 cm (n = 38) 61.07% pT2c >7 cm (n = 13) 46.15% T1NOR0 +T2NOR0 pT1a ≤2 cm (n = 68) 79.15% 0.026 pT1b >2 to 3 cm (n = 99) 79.28% pT2a >3 to 5 cm (n = 107) 66.41% pT2b >5 to 7 cm (n = 38) 61.07% pT2c >7 cm (n = 13) 46.15% No significant financial relationships to disclose.